Skip to content

Mesoblast

US · MESO #2849 by market cap Listed 2015
10.89 -0.29 -2.59%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.04 In line with history 66th percentile
5-year average 2.03 · #307 of 514 in Biotechnology
P/E ratio -30.16 Cheap vs history 4th percentile
5-year average -11.04 · forward -74.13
P/S ratio 14.36 Cheap vs history 1st percentile
5-year average 101.50 · forward 10.38 · #198 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Mesoblast (MESO) 1.42B -24.75 2.49 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value18.27 Economic moatNone UncertaintyVery High

Trading 67.7% below Morningstar's fair value estimate.

Fair value

Mesoblast Ltd is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 27% discount to our quantitative fair value estimate of $18.27 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Mesoblast discussion 0 comments

Add a comment